Clinical significance of serum synaptophysin like 1 protein levels in breast cancer

Abstract

Abstract Background: Mammography which is used for screening breast cancer (BC) has limitations such as decreased sensitivity in dense breasts, requiring additional imaging and leading to unnecessary treatment. In our study, we aimed to investigate the relationship between serum synaptophysin-like protein 1 (SYPL1) value and BC. Method: The study group consisted of 80 female patients with a histopathological diagnosis of invasive BC and didn’t receive any radiotherapy/chemotherapy. The control group 72 women with noprevious history of breast disease and evaluated as Breast Imaging Reporting and Data Systems (BI-RADS 1-2) on imaging. Results: SYPL1 level was found to be statistically significant in diagnosing BC. The point of serum SYPL1 was sensitivity: 48.75%; specificity: 80.56%. There wasn’t statistically significant correlation between serum SYPL1 and tumor diameter, lymph node metastasis, distant organ metastasis, and stage. They were correlated with BI-RADS and serum SYPL1 wasn’t correlated with breast density. Conclusion: The serum SYPL1 maintained a higher discriminatory ability for BC. The serum SYPL1 level can be used with high specificity in the diagnosis of BC. Although SYPL1 has low diagnostic value in BC by itself, it may be included in BC screening in combination with other because it isn’t affected by breast density.